Synergistic Biotherapeutic Agent Delivery Systems

Publication ID: 24-11857670_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Biotherapeutic Agent Delivery Systems,” Published Technical Disclosure No. 24-11857670_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857670_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,670.

Summary of the Inventive Concept

The invention integrates nanoporous implantable canisters with cutting-edge technologies like AI, IoT, blockchain, and advanced materials to create a new generation of personalized, adaptive, and efficient biotherapeutic agent delivery systems.

Background and Problem Solved

The original patent provided a biocompatible, nanoporous device for delivering cellular and biotherapeutic agents. However, it lacked real-time monitoring, personalized medicine capabilities, and advanced integration with other technologies. The new inventive concept addresses these limitations by combining the patented nanoporous canister with AI, IoT, blockchain, and novel materials to create a more powerful, adaptive, and efficient system.

Detailed Description of the Inventive Concept

The synergistic biotherapeutic agent delivery system comprises a nanoporous canister integrated with an AI-powered sensor for real-time monitoring of agent release, a blockchain-secured, patient-specific biotherapeutic agent, and IoT-enabled monitoring to track agent efficacy. The system can be further enhanced with modular, 3D-printed, nanoscale-patterned surfaces for tissue integration and machine learning algorithms for predicting optimal agent release profiles. The hybrid, implantable canister combines a nanoporous, metallic outer shell with a polymeric, nanoscale-patterned inner surface to enhance agent stability and provide structural support.

Novelty and Inventive Step

The new inventive concept's integration of AI, IoT, blockchain, and advanced materials with the patented nanoporous canister provides a non-obvious and novel solution for personalized, adaptive, and efficient biotherapeutic agent delivery. The inventive step lies in the synergistic combination of these distinct technologies to create a more powerful system.

Alternative Embodiments and Variations

Alternative embodiments may include variations in the AI algorithm, IoT connectivity, blockchain security, and materials used. Additionally, the system could be adapted for different types of biotherapeutic agents, tissues, or diseases, ensuring broad conceptual coverage.

Potential Commercial Applications and Market

The synergistic biotherapeutic agent delivery system has significant commercial potential in the fields of personalized medicine, tissue engineering, and regenerative medicine. The target market includes pharmaceutical companies, medical device manufacturers, and healthcare providers seeking to improve treatment outcomes and patient care.

CPC Classifications

Section	Class	Group
A	A61	A61K9/0024
A	A61	A61F2/022
A	A61	A61K31/337
A	A61	A61K31/397
A	A61	A61K31/436
A	A61	A61K31/65
A	A61	A61K31/7036
A	A61	A61K35/28
A	A61	A61K38/14
A	A61	A61K38/1866
A	A61	A61K38/22
A	A61	A61K39/395
A	A61	A61K47/02
A	A61	A61M39/0247
A	A61	A61M2039/027
A	A61	A61M2039/0261
A	A61	A61M2039/0276
A	A61	A61M2205/04

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biomedical engineering, specifically implantable drug delivery systems, biomaterials, and nanoscale medical device design with expertise in materials science, nanotechnology, and biocompatible device fabrication

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or materials scientist with advanced degree, working knowledge of nanoporous materials, implantable medical devices, and experience in designing drug delivery systems with interdisciplinary technological integration

Obviousness Rationale

A PHOSITA would recognize that integrating emerging digital technologies like AI, IoT, and blockchain with existing nanoporous implantable canisters represents a predictable technological evolution. The source patent's foundational nanoporous metallic canister design provides a clear technological platform for incorporating advanced monitoring and personalization technologies. The proposed variations represent logical extensions of the original patent's core principles of controlled therapeutic agent delivery.

Obvious Combinations & Variations

Source Patent Element

Nanoscale through-porous metallic shell with controlled agent secretion

PTD Variation

AI-powered sensor integrated with nanoporous canister for real-time monitoring of agent release

Obviousness Reasoning

Adding sensor technologies to medical implants is a known technique in biomedical engineering, representing a predictable application of digital monitoring to existing device architectures

Source Patent Element

Interior chamber for stabilizing metabolically active agents

PTD Variation

Polymeric, nanoscale-patterned inner surface to enhance agent stability

Obviousness Reasoning

Material surface modifications to improve agent stability are routine design choices for a PHOSITA seeking to optimize drug delivery performance

Source Patent Element

Implantable canister with nanoporous structure

PTD Variation

3D-printed, nanoscale-patterned surface for enhanced tissue integration

Obviousness Reasoning

Advanced manufacturing techniques like 3D printing represent a predictable method for creating sophisticated surface geometries in medical implant design

Source Patent Element

Controlled secretion of metabolically active agent

PTD Variation

Machine learning algorithm for predicting optimal agent release profiles

Obviousness Reasoning

Applying computational predictive techniques to optimize drug delivery represents an obvious technological progression for a skilled practitioner

Source Patent Element

Nanoporous metallic shell defining diffusion channels

PTD Variation

Blockchain-secured, patient-specific biotherapeutic agent delivery

Obviousness Reasoning

Personalizing medical technologies through digital security and patient-specific protocols is a foreseeable technological development in precision medicine

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857670 and the disclosed technological variations, a person of ordinary skill in the art would find the proposed biotherapeutic agent delivery system variations obvious and non-patentable, as they represent predictable combinations of known techniques in nanoporous implantable device design and digital medical technologies.

Original Patent Information

Patent Number	US 11,857,670
Title	Implantable cellular and biotherapeutic agent delivery canister
Assignee(s)	NanoVault Medical LLC